Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025
Elanco Receives FDA Approval For Credelio Quattro, The Broadest Canine Oral Parasiticide Protection In A Single Monthly Dose; Launch Expected In Q1 2025
- Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first and only canine oral parasiticide to protect against six parasites, including fleas, ticks, heartworms, roundworms, hookwormsii and three different species of tapeworm that other brands skip creating a gap in coverageiii
- Warming temperatures and changing consumer habits have increased parasite pressure and spread across geographies, bringing with them increased public health risk.
- Experts recommend monthly treatment for zoonotic parasitesiv, like Echinococcus granulosus, a type of tapeworm.
- Credelio Quattro launch expected in first quarter of 2025
- Credelio Quattro（洛替蘭，莫西汀，普拉西奎酮和吡喹酮可咀嚼片）是首款也是唯一的可以保護犬免受六種寄生蟲侵害的口服寵物藥，在其他品牌遺漏的跳蚤、蜱、心絲蟲、蛔蟲、鉤蟲和三種不同種類的絛蟲之外提供覆蓋的產品，在此填補了覆蓋範圍的空白。
- 氣溫升高和消費習慣改變增加了寄生蟲壓力並跨越地理分佈，帶來了增加的公共衛生風險。
- 專家建議對於人畜共患寄生蟲（如細辛粒蟯蟲，一種絛蟲）進行每月治療。
- Credelio Quattro計劃於2025年第一季度推出。
GREENFIELD, Ind., Oct. 7, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the U.S. Food and Drug Administration (FDA) has approved Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), becoming the broadest approved canine oral parasiticide with its protection against six types of parasites—fleas, ticks, heartworms, and the three risky intestinal parasites—roundworms, hookwormsii and tapeworms. Credelio Quattro is a single, monthly chewable tablet for dogs eight weeks of age or older.
印第安納州格林菲爾德，2024年10月7日/PRNewswire/-- elanco animal health（紐交所：ELAN）今天宣佈美國食品和藥物管理局（FDA）已批准Credelio Quattro（洛替蘭，莫西汀，普拉西奎酮和吡喹酮可咀嚼片），成爲最廣泛的獲批口服犬用寵物藥，可防範六種寄生蟲—蚤、蜱、心絲蟲以及三種具風險的腸道寄生蟲—蛔蟲、鉤蟲和絛蟲。Credelio Quattro是針對八週齡或以上犬隻的單一，每月一次的可咀嚼片。
